Switch theme
Sign up to access all valuation multiples
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
1887
138.1K+
LTM Revenue $89.8B
LTM EBITDA $32.5B
$383B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Johnson & Johnson has a last 12-month revenue of $89.8B and a last 12-month EBITDA of $32.5B.
In the most recent fiscal year, Johnson & Johnson achieved revenue of $88.8B and an EBITDA of $24.8B.
Johnson & Johnson expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Johnson & Johnson valuation multiples based on analyst estimates| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | $89.8B | XXX | XXX | XXX | XXX |
| Gross Profit | $65.3B | XXX | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | XXX | XXX | XXX |
| EBITDA | $32.5B | XXX | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | XXX | XXX | XXX |
| EBIT | $27.9B | XXX | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | XXX | XXX | XXX |
| Net Profit | $24.8B | XXX | XXX | XXX | XXX |
| Net Margin | 28% | XXX | XXX | XXX | XXX |
| Net Debt | $12.5B | XXX | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Johnson & Johnson's stock price is $154.
Johnson & Johnson has current market cap of $370B, and EV of $383B.
See Johnson & Johnson trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $383B | $370B | XXX | XXX | XXX | XXX | $10.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Johnson & Johnson has market cap of $370B and EV of $383B.
Johnson & Johnson's trades at 4.3x EV/LTM Revenue multiple, and 11.8x EV/LTM EBITDA.
Equity research analysts estimate Johnson & Johnson's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Johnson & Johnson has a P/E ratio of 14.9x.
See valuation multiples for Johnson & Johnson and 10K+ public comps| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Market cap (current) | $370B | XXX | XXX | XXX | XXX |
| EV (current) | $383B | XXX | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | XXX | XXX | XXX |
| EV/EBITDA | 11.8x | XXX | XXX | XXX | XXX |
| EV/EBIT | 13.7x | XXX | XXX | XXX | XXX |
| EV/Gross Profit | 5.9x | XXX | XXX | XXX | XXX |
| P/E | 14.9x | XXX | XXX | XXX | XXX |
| EV/FCF | 17.2x | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJohnson & Johnson's last 12 month revenue growth is 3%
Johnson & Johnson's revenue per employee for the last 12 months averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Johnson & Johnson's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Johnson & Johnson's rule of X is 45% (another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Johnson & Johnson and other 10K+ public comps| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | XXX | XXX | XXX |
| Bessemer Rule of X | 45% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.6M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 44% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Johnson & Johnson acquired XXX companies to date.
Last acquisition by Johnson & Johnson was XXXXXXXX, XXXXX XXXXX XXXXXX . Johnson & Johnson acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Johnson & Johnson founded? | Johnson & Johnson was founded in 1887. |
| Where is Johnson & Johnson headquartered? | Johnson & Johnson is headquartered in United States of America. |
| How many employees does Johnson & Johnson have? | As of today, Johnson & Johnson has 138.1K+ employees. |
| Who is the CEO of Johnson & Johnson? | Johnson & Johnson's CEO is Mr. Joaquin Duato. |
| Is Johnson & Johnson publicy listed? | Yes, Johnson & Johnson is a public company listed on NYS. |
| What is the stock symbol of Johnson & Johnson? | Johnson & Johnson trades under JNJ ticker. |
| When did Johnson & Johnson go public? | Johnson & Johnson went public in 1944. |
| Who are competitors of Johnson & Johnson? | Similar companies to Johnson & Johnson include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Johnson & Johnson? | Johnson & Johnson's current market cap is $370B |
| What is the current revenue of Johnson & Johnson? | Johnson & Johnson's last 12 months revenue is $89.8B. |
| What is the current revenue growth of Johnson & Johnson? | Johnson & Johnson revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Johnson & Johnson? | Current revenue multiple of Johnson & Johnson is 4.3x. |
| Is Johnson & Johnson profitable? | Yes, Johnson & Johnson is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Johnson & Johnson? | Johnson & Johnson's last 12 months EBITDA is $32.5B. |
| What is Johnson & Johnson's EBITDA margin? | Johnson & Johnson's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Johnson & Johnson? | Current EBITDA multiple of Johnson & Johnson is 11.8x. |
| What is the current FCF of Johnson & Johnson? | Johnson & Johnson's last 12 months FCF is $22.3B. |
| What is Johnson & Johnson's FCF margin? | Johnson & Johnson's last 12 months FCF margin is 25%. |
| What is the current EV/FCF multiple of Johnson & Johnson? | Current FCF multiple of Johnson & Johnson is 17.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
